US FDA clears Hemispherian’s IND application for first-in-class glioblastoma therapeutic, GLIX1

Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, announced that the US Food and Drug Administration (FDA) has cleared the company's

To access the full article, please log in or subscribe.